Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | PDCD4 | Q53EL6 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | GLS2 | Q9UI32 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | DNTT | P04053 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837979 | 0.86 | GRIK1 (0.41) | CA2PDCD4 | |
| SCHEMBL9326304 | 0.80 | PRKCD (0.39) | PDCD4CYP3A4CYP2C19 | |
| SCHEMBL9766944 | 0.76 | CYP3A4 (0.34) | ZDHHC7PDCD4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9746758 | 0.74 | PDCD4 (0.34) | PDCD4CYP3A4CYP2C9CYP2C19NAAA | |
| SCHEMBL10576887 | 0.72 | ACHE (0.39) | PDCD4CYP2C9CYP2C19 | |
| SCHEMBL7302029 | 0.72 | ACHE (0.39) | PDCD4CYP2C9CYP2C19 | |
| SCHEMBL7298216 | 0.72 | ACHE (0.39) | PDCD4CYP2C9CYP2C19 | |
| SCHEMBL21356697 | 0.72 | CA2 (0.70) | CA1CA2ZDHHC7BIRC2ABCB1 | |
| SCHEMBL18429981 | 0.72 | CA2 (0.70) | CA1CA2ZDHHC7BIRC2ABCB1 | |
| SCHEMBL21356686 | 0.72 | CA2 (0.70) | CA1CA2ZDHHC7BIRC2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5059611-A | Treating psoriasis and modifying calcium homeostatis | ALLERGAN, INC. (US) | 1991-10-22 | — | — | US | claimed |
| EP-0369812-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-05-23 | — | — | EP | claimed |
| US-5541221-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0637240-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS | ALLERGAN, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5387606-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN, INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5268387-A | Containing ester or carbamate group | ALLERGAN, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| WO-1993021915-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING BONE LOSS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES | ALLERGAN, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| US-5059611-A | Treating psoriasis and modifying calcium homeostatis | ALLERGAN, INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0369812-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-05-23 | — | — | EP | disclosed |